Efficacy and Safety Study of Deferred Stenting in Patients With STEMI

NACompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

July 31, 2015

Conditions
ST-segment Elevation Myocardial Infarction
Interventions
PROCEDURE

Deferred coronary stenting

Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.

PROCEDURE

Immediate coronary stenting

Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.

Trial Locations (1)

136-705

Korea University Anam Hospital, Seoul

All Listed Sponsors
collaborator

Terumo Corporation

INDUSTRY

lead

Korea University Anam Hospital

OTHER

NCT02324348 - Efficacy and Safety Study of Deferred Stenting in Patients With STEMI | Biotech Hunter | Biotech Hunter